在患有COVID-19的重症患者中严重的模具真菌感染
Despoina Koulenti1,2, Elisabeth Paramythiotou3, Maria Panagiota Almyroudi4
1Department of Critical Care Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Future microbiology
|May 3, 2024
概括
重症COVID-19患者面临侵入性真菌联合感染的风险增加,特别是来自Aspergillus和Mucor物种. 这些真菌感染加剧了患者的结果,在诊断和治疗方面带来了独特的挑战.
科学领域:
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
- 菌类学 菌类学是指菌类学.
背景情况:
- 在全球范围内,SARS-CoV-2大流行严重影响了医疗保健系统.
- 侵袭性真菌共感染,特别是菌感染,在重症COVID-19患者中增加.
- 这些共同感染在重症监护病房带来了诊断和治疗方面的挑战.
研究的目的:
- 在重症COVID-19患者中审查有关侵入性菌感染 (Aspergillus和Mucor物种) 的当前知识.
- 讨论发病率,发病因子,诊断,治疗和预防策略.
- 突出新出现的风险因素及其对患者结果的影响.
主要方法:
- 现有文献的叙述性审查.
- 专注于患有侵袭性菌感染的重症COVID-19患者.
- 对发病率,发病因子,诊断,治疗和预防的分析.
主要成果:
- 与大流行前水平相比,COVID-19患者的侵入性菌共同感染发生率较高.
- 传统的风险因素往往不存在,这表明了新的决定因素.
- 模具共感染与患者的治疗结果明显恶化有关.
结论:
- 侵入性阿斯伯吉勒斯和粘菌感染是严重的COVID-19中显著的并发病.
- 了解独特的风险因素和实施有针对性的干预措施至关重要.
- 及时诊断和治疗对于改善这些复杂病例的结果至关重要.
相关概念视频
Pulmonary Tuberculosis I
241
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
241
Transmission-based Precautions II: Airborne and Protective Environment
1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Acute Respiratory Failure-V
136
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
136
Pneumonia IV: Management
323
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323
Pneumonia III: Complications and Assessment
204
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
204
Pneumonia II: Pathophysiology
261
The pathophysiology of pneumonia involves the following steps:
261


